Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 169

1.

Low Admission Plasma Gelsolin Concentrations Identify Community-acquired Pneumonia Patients at High Risk for Severe Outcomes.

Self WH, Wunderink RG, DiNubile MJ, Stossel TP, Levinson SL, Williams DJ, Anderson EJ, Bramley AM, Jain S, Edwards KM, Grijalva CG.

Clin Infect Dis. 2019 Sep 13;69(7):1218-1225. doi: 10.1093/cid/ciy1049.

PMID:
30561561
2.

Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of Age.

Garland SM, Joura EA, Ault KA, Bosch FX, Brown DR, Castellsagué X, Ferenczy A, Ferris DG, Giuliano AR, Hernandez-Avila M, Huh WK, Iversen OE, Kjaer SK, Kurman RJ, Luna J, Monsonego J, Muñoz N, Paavonen J, Pitisuttihum P, Ronnett BM, Steben M, Stoler MH, Wheeler CM, Wiley DJ, Perez G, Saah AJ, Luxembourg A, Li S, DiNubile MJ, Wagner M, Velicer C.

Obstet Gynecol. 2018 Aug;132(2):261-270. doi: 10.1097/AOG.0000000000002736.

PMID:
29995724
3.

Risk prediction for Staphylococcus aureus surgical site infection following cardiothoracic surgery; A secondary analysis of the V710-P003 trial.

Paling FP, Olsen K, Ohneberg K, Wolkewitz M, Fowler VG Jr, DiNubile MJ, Jafri HS, Sifakis F, Bonten MJM, Harbarth SJ, Kluytmans JAJW.

PLoS One. 2018 Mar 21;13(3):e0193445. doi: 10.1371/journal.pone.0193445. eCollection 2018.

4.

Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.

Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, Haider S, Ullmann AJ, Katayama Y, Brown J, Mullane KM, Boeckh M, Blumberg EA, Einsele H, Snydman DR, Kanda Y, DiNubile MJ, Teal VL, Wan H, Murata Y, Kartsonis NA, Leavitt RY, Badshah C.

N Engl J Med. 2017 Dec 21;377(25):2433-2444. doi: 10.1056/NEJMoa1706640. Epub 2017 Dec 6.

5.

Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK Studies.

Squires K, Bekker LG, Katlama C, Yazdanpanah Y, Zhou Y, Rodgers AJ, DiNubile MJ, Sklar PA, Leavitt RY, Teppler H.

Open Forum Infect Dis. 2017 Feb 28;4(1):ofw047. doi: 10.1093/ofid/ofw047. eCollection 2017 Winter.

6.

Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women.

Iversen OE, Miranda MJ, Ulied A, Soerdal T, Lazarus E, Chokephaibulkit K, Block SL, Skrivanek A, Nur Azurah AG, Fong SM, Dvorak V, Kim KH, Cestero RM, Berkovitch M, Ceyhan M, Ellison MC, Ritter MA, Yuan SS, DiNubile MJ, Saah AJ, Luxembourg A.

JAMA. 2016 Dec 13;316(22):2411-2421. doi: 10.1001/jama.2016.17615.

PMID:
27893068
7.

Noninferior Antibiotics: When Is "Not Bad" "Good Enough"?

DiNubile MJ.

Open Forum Infect Dis. 2016 May 25;3(3):ofw110. doi: 10.1093/ofid/ofw110. eCollection 2016 Sep.

8.

Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience.

Garland SM, Kjaer SK, Muñoz N, Block SL, Brown DR, DiNubile MJ, Lindsay BR, Kuter BJ, Perez G, Dominiak-Felden G, Saah AJ, Drury R, Das R, Velicer C.

Clin Infect Dis. 2016 Aug 15;63(4):519-27. doi: 10.1093/cid/ciw354. Epub 2016 May 26. Review.

9.

Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE.

Buti M, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, Gilbert C, Palcza J, Howe AY, DiNubile MJ, Robertson MN, Wahl J, Barr E, Forns X.

Clin Infect Dis. 2016 Jan 1;62(1):32-6. doi: 10.1093/cid/civ722. Epub 2015 Sep 14.

PMID:
26371152
10.

Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir.

Liu R, Curry S, McMonagle P, Yeh WW, Ludmerer SW, Jumes PA, Marshall WL, Kong S, Ingravallo P, Black S, Pak I, DiNubile MJ, Howe AY.

Antimicrob Agents Chemother. 2015 Nov;59(11):6922-9. doi: 10.1128/AAC.01390-15. Epub 2015 Aug 24.

11.

Prednisolone or Pentoxifylline for Alcoholic Hepatitis.

DiNubile MJ.

N Engl J Med. 2015 Jul 16;373(3):281-2. doi: 10.1056/NEJMc1506342. No abstract available.

PMID:
26176389
12.

Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.

Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, Brown DD, Wan S, DiNubile MJ, Nguyen BY, Robertson MN, Wahl J, Barr E, Butterton JR.

Ann Intern Med. 2015 Jul 7;163(1):1-13. doi: 10.7326/M15-0785.

PMID:
25909356
13.

Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent.

Forns X, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, Gilbert C, Palcza J, Howe AY, DiNubile MJ, Robertson MN, Wahl J, Barr E, Buti M.

J Hepatol. 2015 Sep;63(3):564-72. doi: 10.1016/j.jhep.2015.04.009. Epub 2015 Apr 18.

PMID:
25895428
14.

Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/Ribavirin.

Howe JA, Long J, Black S, Chase R, McMonagle P, Curry S, Thompson S, DiNubile MJ, Howe AY.

Open Forum Infect Dis. 2014 Sep 16;1(2):ofu078. doi: 10.1093/ofid/ofu078. eCollection 2014 Sep.

15.

Staphylococcus aureus Infections After Elective Cardiothoracic Surgery: Observations From an International Randomized Placebo-Controlled Trial of an Investigational S aureus Vaccine.

Allen KB, Fowler VG Jr, Gammie JS, Hartzel JS, Onorato MT, DiNubile MJ, Sobanjo-Ter Meulen A.

Open Forum Infect Dis. 2014 Aug 26;1(2):ofu071. doi: 10.1093/ofid/ofu071. eCollection 2014 Sep.

16.

Safety Profile of the Merck Human Immunodeficiency Virus-1 Clade B gag DNA Plasmid Vaccine With and Without Adjuvants.

Quirk EK, Brown EL, Leavitt RY, Mogg R, Mehrotra DV, Evans RK, DiNubile MJ, Robertson MN.

Open Forum Infect Dis. 2014 May 17;1(1):ofu016. doi: 10.1093/ofid/ofu016. eCollection 2014 Mar.

17.

Trials and tribulations of noninferiority: caveat emptor.

DiNubile MJ.

Clin Infect Dis. 2015 Apr 15;60(8):1290-1. doi: 10.1093/cid/civ022. Epub 2015 Jan 21. No abstract available.

PMID:
25609683
18.

Mortality among recipients of the Merck V710 Staphylococcus aureus vaccine after postoperative S. aureus infections: an analysis of possible contributing host factors.

McNeely TB, Shah NA, Fridman A, Joshi A, Hartzel JS, Keshari RS, Lupu F, DiNubile MJ.

Hum Vaccin Immunother. 2014;10(12):3513-6. doi: 10.4161/hv.34407.

19.

Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection.

Howe AY, Black S, Curry S, Ludmerer SW, Liu R, Barnard RJ, Newhard W, Hwang PM, Nickle D, Gilbert C, Caro L, DiNubile MJ, Mobashery N.

Clin Infect Dis. 2014 Dec 15;59(12):1657-65. doi: 10.1093/cid/ciu696. Epub 2014 Sep 28.

PMID:
25266289
20.

Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials.

Vierling JM, Zeuzem S, Poordad F, Bronowicki JP, Manns MP, Bacon BR, Esteban R, Flamm SL, Kwo PY, Pedicone LD, Deng W, Dutko FJ, DiNubile MJ, Koury KJ, Helmond FA, Wahl J, Bruno S.

J Hepatol. 2014 Aug;61(2):200-9. doi: 10.1016/j.jhep.2014.03.022. Epub 2014 Apr 18.

PMID:
24747798
21.

Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis.

Rodriguez-Torres M, Stoehr A, Gane EJ, Serfaty L, Lawitz E, Zhou A, Bourque M, Bhanja S, Strizki J, Barnard RJ, Hwang PM, DiNubile MJ, Mobashery N.

Clin Gastroenterol Hepatol. 2014 Jun;12(6):1029-37.e5. doi: 10.1016/j.cgh.2013.09.067. Epub 2013 Oct 10.

PMID:
24120953
22.

Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis.

Barnard RJ, McHale CM, Newhard W, Cheney CA, Graham DJ, Himmelberger AL, Strizki J, Hwang PM, Rivera AA, Reeves JD, Nickle D, Dinubile MJ, Hazuda DJ, Mobashery N.

Virology. 2013 Sep 1;443(2):278-84. doi: 10.1016/j.virol.2013.05.013. Epub 2013 Jun 10.

23.

Rigor in the design of observational noninferiority trials.

Dinubile MJ.

Clin Infect Dis. 2013 Oct;57(7):1056. doi: 10.1093/cid/cit386. Epub 2013 Jun 11. No abstract available.

PMID:
23759347
24.

Seminal human immunodeficiency virus blips and structured natural conception in serodiscordant couples.

Mounzer KC, DiNubile MJ.

J Infect Dis. 2013 Aug 15;208(4):710-1. doi: 10.1093/infdis/jit219. Epub 2013 May 10. No abstract available.

PMID:
23667137
25.

Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial.

Fowler VG, Allen KB, Moreira ED, Moustafa M, Isgro F, Boucher HW, Corey GR, Carmeli Y, Betts R, Hartzel JS, Chan IS, McNeely TB, Kartsonis NA, Guris D, Onorato MT, Smugar SS, DiNubile MJ, Sobanjo-ter Meulen A.

JAMA. 2013 Apr 3;309(13):1368-78. doi: 10.1001/jama.2013.3010.

PMID:
23549582
26.

Bias and asymmetry in sequential noninferiority-superiority trial designs.

Dinubile MJ.

Clin Infect Dis. 2013 Jun;56(12):1841-2. doi: 10.1093/cid/cit148. Epub 2013 Mar 13. No abstract available.

PMID:
23487371
27.

Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.

Rockstroh JK, DeJesus E, Lennox JL, Yazdanpanah Y, Saag MS, Wan H, Rodgers AJ, Walker ML, Miller M, DiNubile MJ, Nguyen BY, Teppler H, Leavitt R, Sklar P; STARTMRK Investigators.

J Acquir Immune Defic Syndr. 2013 May 1;63(1):77-85. doi: 10.1097/QAI.0b013e31828ace69.

PMID:
23412015
28.

Plasma gelsolin levels in the diagnosis, prognosis, and treatment of lung complications of prematurity.

DiNubile MJ.

Am J Respir Crit Care Med. 2012 Dec 1;186(11):1195-6. No abstract available.

PMID:
23204381
29.

Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK.

DeJesus E, Rockstroh JK, Lennox JL, Saag MS, Lazzarin A, Zhao J, Wan H, Rodgers AJ, Walker ML, Miller M, DiNubile MJ, Nguyen BY, Teppler H, Leavitt R, Sklar P; STARTMRK Investigators.

HIV Clin Trials. 2012 Jul-Aug;13(4):228-32. doi: 10.1310/hct1304-228. Erratum in: HIV Clin Trials. 2012 Sep-Oct;13(5):preceding 233.

PMID:
22849964
30.

Phase IIa study of the immunogenicity and safety of the novel Staphylococcus aureus vaccine V710 in adults with end-stage renal disease receiving hemodialysis.

Moustafa M, Aronoff GR, Chandran C, Hartzel JS, Smugar SS, Galphin CM, Mailloux LU, Brown E, Dinubile MJ, Kartsonis NA, Guris D.

Clin Vaccine Immunol. 2012 Sep;19(9):1509-16. doi: 10.1128/CVI.00034-12. Epub 2012 Jul 25.

31.

Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin.

Jacobson IM, Marcellin P, Zeuzem S, Sulkowski MS, Esteban R, Poordad F, Bruno S, Burroughs MH, Pedicone LD, Boparai N, Deng W, DiNubile MJ, Gottesdiener KM, Brass CA, Albrecht JK, Bronowicki JP.

Hepatology. 2012 Aug;56(2):567-75. doi: 10.1002/hep.25865. Epub 2012 Jun 29.

PMID:
22619063
32.

Burden of rotavirus hospitalisations in young children in three paediatric hospitals in the United States determined by active surveillance compared to standard indirect methods.

Matson DO, Staat MA, Azimi P, Itzler R, Bernstein DI, Ward RL, Dahiya R, DiNubile MJ, Barnes-Eley M, Berke T.

J Paediatr Child Health. 2012 Aug;48(8):698-704. doi: 10.1111/j.1440-1754.2012.02445.x. Epub 2012 Apr 25.

PMID:
22530784
33.

Transesophageal echocardiograms in patients with catheter-derived Staphylococcus aureus bacteremia.

DiNubile MJ.

Am J Med. 2012 Jul;125(7):628-9. doi: 10.1016/j.amjmed.2011.09.032. Epub 2012 Apr 11. No abstract available.

PMID:
22502954
34.

Serotype replacement after pneumococcal vaccination.

DiNubile MJ.

Lancet. 2012 Apr 14;379(9824):1388; author reply 1388-9. doi: 10.1016/S0140-6736(12)60590-X. No abstract available.

PMID:
22500870
35.

Distribution of rotavirus genotypes causing nosocomial and community-acquired acute gastroenteritis at the Children's Hospital of Philadelphia in the new rotavirus vaccine era.

Clark HF, Lawley D, DiStefano D, Matthijnssens J, Dinubile MJ.

Hum Vaccin. 2011 Nov;7(11):1118-23. doi: 10.4161/hv.7.11.17820. Epub 2011 Nov 1.

PMID:
22048265
36.

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial.

Eron JJ Jr, Rockstroh JK, Reynes J, Andrade-Villanueva J, Ramalho-Madruga JV, Bekker LG, Young B, Katlama C, Gatell-Artigas JM, Arribas JR, Nelson M, Campbell H, Zhao J, Rodgers AJ, Rizk ML, Wenning L, Miller MD, Hazuda D, DiNubile MJ, Leavitt R, Isaacs R, Robertson MN, Sklar P, Nguyen BY; QDMRK Investigators.

Lancet Infect Dis. 2011 Dec;11(12):907-15. doi: 10.1016/S1473-3099(11)70196-7. Epub 2011 Sep 18. Erratum in: Lancet Infect Dis. 2011 Dec;11(12):895. Dosage error in article text.

PMID:
21933752
37.

Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.

Rockstroh JK, Lennox JL, Dejesus E, Saag MS, Lazzarin A, Wan H, Walker ML, Xu X, Zhao J, Teppler H, Dinubile MJ, Rodgers AJ, Nguyen BY, Leavitt R, Sklar P; STARTMRK Investigators.

Clin Infect Dis. 2011 Oct;53(8):807-16. doi: 10.1093/cid/cir510.

PMID:
21921224
38.

Leprosy: forgotten, but not gone (yet).

Dinubile MJ, Keystone JS.

Int J Dermatol. 2011 Aug;50(8):1024-6. doi: 10.1111/j.1365-4632.2011.04961.x. Epub 2011 Jul 5. No abstract available.

PMID:
21726216
39.

Boceprevir for untreated chronic HCV genotype 1 infection.

Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP; SPRINT-2 Investigators.

N Engl J Med. 2011 Mar 31;364(13):1195-206. doi: 10.1056/NEJMoa1010494.

40.

Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen).

Dennehy PH, Vesikari T, Matson DO, Itzler RF, Dallas MJ, Goveia MG, DiNubile MJ, Heaton PM, Ciarlet M.

Hum Vaccin. 2011 May;7(5):563-8. Epub 2011 May 1.

PMID:
21441783
41.

Therapeutic potential of plasma gelsolin administration in a rat model of sepsis.

Cohen TS, Bucki R, Byfield FJ, Ciccarelli NJ, Rosenberg B, DiNubile MJ, Janmey PA, Margulies SS.

Cytokine. 2011 Jun;54(3):235-8. doi: 10.1016/j.cyto.2011.02.006. Epub 2011 Mar 21.

42.

An unusual outbreak of rotavirus genotype G2P[6] during the 2005-2006 epidemic season in Philadelphia.

Clark HF, Lawley D, DiStefano D, Maliga M, Kilby B, Kulnis G, Mallette L, DiNubile MJ.

Diagn Microbiol Infect Dis. 2011 Jun;70(2):218-22. doi: 10.1016/j.diagmicrobio.2010.12.014. Epub 2011 Mar 12.

PMID:
21398071
43.

Pentavalent rotavirus vaccine in developing countries: safety and health care resource utilization.

Christie CD, Duncan ND, Thame KA, Onorato MT, Smith HD, Malcolm LG, Itzler RF, Dinubile MJ, Heaton PM.

Pediatrics. 2010 Dec;126(6):e1499-506. doi: 10.1542/peds.2010-1240. Epub 2010 Nov 29.

PMID:
21115586
44.

Safety and immunogenicity of a novel Staphylococcus aureus vaccine: results from the first study of the vaccine dose range in humans.

Harro C, Betts R, Orenstein W, Kwak EJ, Greenberg HE, Onorato MT, Hartzel J, Lipka J, DiNubile MJ, Kartsonis N.

Clin Vaccine Immunol. 2010 Dec;17(12):1868-74. doi: 10.1128/CVI.00356-10. Epub 2010 Oct 13.

45.

Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort.

Hiemenz JW, Raad II, Maertens JA, Hachem RY, Saah AJ, Sable CA, Chodakewitz JA, Severino ME, Saddier P, Berman RS, Ryan DM, Dinubile MJ, Patterson TF, Denning DW, Walsh TJ.

Eur J Clin Microbiol Infect Dis. 2010 Nov;29(11):1387-94. doi: 10.1007/s10096-010-1013-0. Epub 2010 Aug 12.

PMID:
20703506
46.

Sustained decline in cases of rotavirus gastroenteritis presenting to the Children's Hospital of Philadelphia in the new rotavirus vaccine era.

Clark HF, Lawley D, Matthijnssens J, DiNubile MJ, Hodinka RL.

Pediatr Infect Dis J. 2010 Aug;29(8):699-702. doi: 10.1097/INF.0b013e3181d73524.

PMID:
20661099
47.

Premastication: a possible missing link?

Dinubile MJ.

Clin Infect Dis. 2010 Jul 15;51(2):252-3. doi: 10.1086/653681. No abstract available.

PMID:
20560737
48.

Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5).

Itzler R, Koch G, Matson DO, Gothefors L, Van Damme P, Dinubile MJ, Heaton PM.

BMC Pediatr. 2010 Jun 11;10:42. doi: 10.1186/1471-2431-10-42.

49.

Unexpectedly high burden of rotavirus gastroenteritis in very young infants.

Clark HF, Marcello AE, Lawley D, Reilly M, DiNubile MJ.

BMC Pediatr. 2010 Jun 11;10:40. doi: 10.1186/1471-2431-10-40.

50.

Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.

Lennox JL, Dejesus E, Berger DS, Lazzarin A, Pollard RB, Ramalho Madruga JV, Zhao J, Wan H, Gilbert CL, Teppler H, Rodgers AJ, Barnard RJ, Miller MD, Dinubile MJ, Nguyen BY, Leavitt R, Sklar P; STARTMRK Investigators.

J Acquir Immune Defic Syndr. 2010 Sep;55(1):39-48. doi: 10.1097/QAI.0b013e3181da1287. Erratum in: J Acquir Immune Defic Syndr. 2011 Dec 1;58(4):e120. Dosage error in article text.

Supplemental Content

Loading ...
Support Center